Lab-on-a-Chip Market Size To Reach $11.45 Billion By 2030

 

Lab-on-a-Chip Market Growth and Trends

The global lab-on-a-chip market size is expected to reach USD 11.45 billion by 2030 and is expected to grow at a CAGR of 9.76% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market is driven by rising investments in healthcare R&D, integration of AI in diagnostics, and government initiatives supporting personalized medicine and decentralized testing.

The lab-on-a-chip market is experiencing significant growth due to advancements in microfluidics technology, which has improved the precision and efficiency of diagnostic processes. In addition, the integration of lab-on-a-chip devices in clinical and research laboratories has streamlined workflows, further reducing the time required for complex analyses. The demand for high-throughput screening in the pharmaceutical and biotechnology industries has also expanded the applications of lab-on-a-chip technology, enabling faster drug discovery and personalized treatment approaches.

Furthermore, the rising adoption of telemedicine and remote patient monitoring has increased the need for portable diagnostic solutions, which has placed lab-on-a-chip as an important component in decentralized healthcare systems. The development of cost-effective manufacturing techniques, including 3D printing and nanofabrication, has enhanced the scalability of lab-on-a-chip production, making these devices more accessible. Moreover, increasing government funding and private investments in healthcare innovation have further accelerated research and commercialization of lab-on-a-chip technologies.

Key market players are adopting various strategies to enhance the effectiveness and reliability of Lab-on-a-Chip technologies by integrating advanced microfluidics, AI-driven analytics, and biomimetic systems. Companies are focusing on improving drug testing accuracy, organ-on-chip models, and point-of-care diagnostics to meet the growing demand for personalized medicine and decentralized healthcare. In September 2024, Emulate, Inc. announced the launch of Chip-R1 Rigid Chip, designed to minimize drug absorption and enhance biological modeling. This innovation addresses the challenge of drug compound loss during in vitro testing, thereby improving the accuracy of pharmacokinetic and toxicological assessments.

Request a free sample copy or view report summary:
Lab-on-a-Chip Market Report

Lab-on-a-Chip Market Report Highlights

• Based on product & service, reagents & consumables dominated the market due to their essential role in diagnostic procedures, ensuring high sensitivity and accuracy. The increasing demand for single-use cartridges and microfluidic reagents has further driven market growth.
• Based on technology, microfluidics technology held the largest revenue share in 2024 due to its ability to enable precise fluid handling at a microscale, improving diagnostic accuracy and efficiency.
• Based on application, clinical diagnostics held the largest revenue share in 2024 due to the increasing need for rapid, cost-effective, and accurate disease detection. The widespread use of Lab-on-a-Chip devices for infectious disease testing, cancer screening, and genetic an a has propelled market growth.
• Based on end use, hospitals, and diagnostic centers held the largest revenue share in 2024 due to their extensive use of lab-on-a-chip technology for diagnostic purposes.
• Based on region, North America dominated the market in 2024 due to the presence of numerous leading pharmaceutical and biotechnology companies, driving the demand for cutting-edge diagnostic and testing solutions.

Lab-on-a-Chip Market Segmentation

Grand View Research has segmented the global lab-on-a-chip market based on product & service, technology, application, end-use, and region:

Lab-on-a-Chip Product & Service Outlook (Revenue, USD Million, 2018–2030)

• Reagents & Consumables
• Instruments
• Software & Services

Lab-on-a-Chip Technology Outlook (Revenue, USD Million, 2018–2030)

• Microfluidics Technology
• Optical Technology
• Electrochemical Technology
• Others

Lab-on-a-Chip Application Outlook (Revenue, USD Million, 2018–2030)

• Clinical Diagnostics
• Drug Discovery & Development
• Others

Lab-on-a-Chip End Use Outlook (Revenue, USD Million, 2018–2030)

• Academic & Research Institutes
• Hospitals & Diagnostic Centers
• Pharmaceutical & Biotechnology Companies
• Others

Dopamine Agonist Market Size To Reach $1.83 Billion By 2030

 

Dopamine Agonist Market Growth & Trends

The global dopamine agonist market size is anticipated to reach USD 1.83 billion by 2030 and is projected to grow at a CAGR of 5.70% during the forecast period, according to a new report by Grand View Research, Inc. The demand for dopamine agonists in neurological treatments, including ergot alkaloids and non-ergot dopamine agonists, is creating significant opportunities in the pharmaceutical sector. These drugs, which have demonstrated effectiveness in managing conditions like Parkinson’s disease, restless legs syndrome (RLS), and hyperprolactinemia, are driving market expansion. Ergot-derived dopamine agonists have long been used in clinical practice, while non-ergot dopamine agonists are gaining preference due to their improved safety profiles and tolerability. With growing clinical evidence supporting their efficacy, the acceptance of dopamine agonists in managing movement disorders continues to rise.

The development of oral and injectable formulations further broadens treatment accessibility and patient preference. Oral dopamine agonists are widely used for chronic conditions like Parkinson’s disease and RLS, allowing for convenient administration and long-term adherence. Injectable formulations, on the other hand, play a crucial role in managing acute or advanced-stage cases where immediate and sustained drug action is required. With pharmaceutical companies focusing on developing innovative drug delivery methods, the market is poised for further growth.

Pharmaceutical companies such as Teva Pharmaceutical Industries Ltd., GSK plc., Supernus Pharmaceuticals, Inc., H. Lundbeck A/S, Amneal Pharmaceuticals LLC, UCB Pharma, Novartis AG, VeroScience LLC., Pfizer Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. are actively contributing to the expansion of the market. These companies are engaged in research and development efforts to improve drug efficacy, safety, and patient compliance, further driving the adoption of these therapies.

Retail pharmacies play an increasing role in the distribution of dopamine agonists, particularly for oral formulations used in chronic disease management. These pharmacies offer not only easy access to medications but also patient education and counseling services to ensure adherence and optimal treatment outcomes. The ability of retail pharmacies to provide consistent medication refills and support makes them a key component in long-term patient care.

Hospital pharmacies remain crucial, especially in the initial stages of treatment, when close monitoring is essential. Parkinson’s disease patients, for instance, often begin therapy under hospital supervision before transitioning to outpatient care. As patients stabilize, retail and specialty pharmacies become primary sources for continued medication access and support services, ensuring uninterrupted treatment for chronic neurological disorders.

As the demand for dopamine agonists continues to rise, challenges such as supply chain management and drug distribution will emerge. Ensuring the consistent availability of both oral and injectable therapies will require a strong logistics infrastructure and a focus on patient education to maximize adherence and therapeutic outcomes. Moreover, continued investment in research and development, particularly for novel delivery systems, presents an opportunity for pharmaceutical companies to cater to a broader patient population and enhance treatment effectiveness.

Request a free sample copy or view report summary:
Dopamine Agonist Market Report

Dopamine Agonist Market Report Highlights

• In 2024, non-ergot dopamine agonists dominated the market, solidifying their position as the preferred treatment option for neurological disorders. Their superior safety profile, improved tolerability, and growing clinical acceptance make them the leading therapy in this class.
• The oral segment dominated the market in 2024. Oral formulations are widely preferred due to their convenience, long-term adherence benefits, and effectiveness in managing chronic conditions like Parkinson’s disease, restless legs syndrome (RLS), and hyperprolactinemia.
• Retail pharmacies emerged as the dominant distribution channel in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using dopamine agonist medications.
• North America led the market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options.

Dopamine Agonist Market Segmentation

Grand View Research has segmented the global dopamine agonist market based on drug, application, route of administration, distribution channel, and region:

Dopamine Agonist Drug Outlook (Revenue, USD Million, 2018–2030)

• Non-ergot Dopamine Agonists
• Ergot Alkaloids

Dopamine Agonist Application Outlook (Revenue, USD Million, 2018–2030)

• Parkinson’s Disease
• Restless Legs Syndrome (RLS)
• Hyperprolactinemia
• Others

Dopamine Agonist Route of Administration Outlook (Revenue, USD Million, 2018–2030)

• Oral
• Injectable
• Others

Dopamine Agonist Distribution Channel Outlook (Revenue, USD Million, 2018–2030)

• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies

Veterinary 3D Printing Market To Reach $196.2 Million By 2030

 August 2025 | Report Format: Electronic (PDF)

The global veterinary 3D printing market size was estimated at USD 112.5 million in 2024 and is projected to reach USD 196.2 million by 2030, growing at a CAGR of 9.82% from 2025 to 2030. Rising adoption of 3D printing in veterinary sciences, R&D initiatives, increasing application of 3D printing in veterinary surgical planning, and the emergence of novel applications are some of the major factors driving this market.

Key Market Trends & Insights

• In terms of region, North America was the largest revenue generating market in 2024.
• Country-wise, Sweden is expected to register the highest CAGR from 2025 to 2030.
• In terms of segment, implants accounted for a revenue of USD 40.9 million in 2024.
• Anatomical Models is the most lucrative product segment registering the fastest growth during the forecast period.

Market Size & Forecast

• 2024 Market Size: USD 112.5 Million
• 2030 Projected Market Size: USD 196.2 Million
• CAGR (2025–2030): 9.82%
• North America: Largest market in 2024

A major driving factor in this market is the continuous research efforts worldwide to discover novel materials to be utilized in printing 3D printed products like prosthetics, orthotics, implants, masks, anatomical models, etc. This research into novel materials is aimed at finding materials that are more efficient and also environmentally friendly. For instance, according to 2025 Elsevier published article explored the use of biowaste for 3D printing.

The research highlighted the potential of biowaste-derived materials as sustainable alternatives for bone tissue engineering by repurposing animal remains, such as bones, to extract Hydroxyapatite, essential for bone regeneration. Additionally, marine biowaste, including fish skin and scales, provided an economical source of collagen, enhancing material sustainability while aligning sustainable development goals focused on health, responsible consumption, and climate action. The study emphasized the advantages of using biowaste over conventional feedstocks, noting its renewable and cost-effective nature. It discussed the extraction of Hydroxyapatite and extracellular matrix (ECM) polymers, which improved printability and bioactivity crucial for effective bone scaffolds.

Despite the promising applications, challenges such as regulatory hurdles and the need for extensive clinical trials persisted before commercialization could occur in the future. Furthermore, localized production limited broader industry investment but could stimulate indigenous technologies for biowaste utilization. Overall, biowaste-derived bioinks may contribute significantly to sustainable practices in regenerative medicine while addressing environmental concerns associated with traditional synthetic materials.

Request a free sample copy or view report summary:
Veterinary 3D Printing Market Report

Veterinary 3D Printing Market Report Highlights

• The implants segment held the highest market share in 2024. This segment comprises 3D printed veterinary implants like TPLO, TPLA, etc. Key factors contributing to this dominance include the ability of these implants to be customized for various animal anatomies, which enhances surgical outcomes, and advancements in technology that allow for biocompatible materials, improving integration and reducing rejection rates.
• The other animals segment, including horses, turtles, birds, livestock animals, etc., is projected to expand at the fastest rate in the forecast period, owing to the growing adoption of 3D printing in the treatment of various ailments and also the emergence of specialized companies focusing on developing 3D printed products for a specific species.
• The surgical planning segment is estimated to grow at the highest rate over the forecast period. This can be due to 3D printing, which creates patient-specific anatomical models and enhances the visualization of complex structures. It enables the creation of customized surgical instruments, patient-specific models, and surgical guides, leading to more efficient and less invasive procedures.
• North America held the largest market share of more than 41% and is expected to grow at the fastest CAGR over the forecast period. Countries from this region, such as the U.S., Canada, and Mexico, are continuously involved in activities to increase and expand the adoption of 3D printed products across the veterinary space.

Veterinary 3D Printing Market Segmentation

Grand View Research has segmented the global veterinary 3D printing market on the basis of product, animal, application, materials, end use, and region:

Veterinary 3D Printing Product Outlook (Revenue, USD Million; 2018–2030)

• Implants
• Prosthetics & Orthotics
• Anatomical Models
• Masks

Veterinary 3D Printing Animal Outlook (Revenue, USD Million; 2018–2030)

• Dogs
• Cats
• Other Animals

Veterinary 3D Printing Application Outlook (Revenue, USD Million; 2018–2030)

• Orthopedics
• Surgical Planning
• Other Applications

Veterinary 3D Printing Material Outlook (Revenue, USD Million; 2018–2030)

• Metals
• Ceramics
• Polymers
• Other Materials

Veterinary 3D Printing End Use Outlook (Revenue, USD Million; 2018–2030)

• Hospitals & Clinics
• Academic & Research Institutions
• Other End use

Inhalable Biologics Market Size To Reach $10.06 Billion By 2030

 

Inhalable Biologics Market Growth & Trends 

The global inhalable biologics market size is anticipated to reach USD 10.06 billion by 2030 and is projected to grow at a CAGR of 17.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growth drivers include the increasing prevalence of respiratory diseases, rising demand for non-invasive drug delivery, and advancements in formulation technologies enhancing biologic stability. The market benefits from patient preference for self-administration, faster drug onset through pulmonary delivery, and research on inhalable monoclonal antibodies, peptides, and RNAi-based therapeutics. Regulatory support and technological innovations further expand market opportunities.

The high prevalence of respiratory conditions, including asthma, COPD, and cystic fibrosis, remains a key growth driver. According to the CDC and ACAAI, asthma affected 7.7% of Americans (24.9 million) in 2023, leading to significant healthcare utilization and costs. Inhalable biologics offer targeted lung delivery with rapid onset, enhancing treatment efficacy while minimizing systemic side effects. Companies such as Ocugen, Moderna, Pfizer-BioNTech, and AstraZeneca are expanding their portfolios through inhaled vaccines and therapeutics. For instance, Ocugen received FDA clearance in January 2025 for a Phase 1 trial of OCU500, an inhaled COVID-19 vaccine, while MannKind Corporation continues to expand Afrezza’s reach, with Indian regulatory approval following positive Phase 3 trial results.

The market pipeline remains active, with inhalable biologics targeting respiratory diseases, diabetes, infectious diseases, and oncology. A notable innovation includes inhalable mRNA therapeutics using lipid nanoparticles (LNPs) functionalized with zwitterionic polymers, as published in the Journal of the American Chemical Society in November 2024, demonstrating stable nebulization and effective pulmonary delivery.

In December 2024, MannKind Corporation and Cipla Ltd. secured CDSCO approval for Afrezza (insulin human) Inhalation Powder for adults in India, following prior approvals in the U.S. and Brazil. Under this strategic initiative, MannKind will supply the product while Cipla manages marketing and distribution, with shipments expected by late 2025. The move aims to strengthen Afrezza’s global presence, particularly in India, where over 74 million adults are affected by diabetes. Afrezza offers a non-injectable, rapid-acting insulin alternative, with quick absorption and a 2-3 hour effect, addressing patient preferences for innovative and patient-centric diabetes management solutions. Cipla’s extensive distribution network is positioned to enhance access and improve patient outcomes across India. Safety measures include precautions for patients with chronic lung diseases due to the risk of bronchospasm.

As part of pipeline advancements in inhalable biologics, Ab Initio Pharma participated as a Silver Sponsor at the 35th Drug Delivery to the Lungs (DDL) Conference from December 11–13, 2024, in Edinburgh. This engagement represents a strategic initiative to highlight its drug delivery solutions, including small molecules, peptides, oligonucleotides, and RNA-based therapies. Key conference features include a presentation on intranasal mRNA delivery and a poster on inhaled oligonucleotides, emphasizing innovation in non-invasive treatment modalities.

These initiatives underscore a growing emphasis on expanding access to inhalable therapies and strengthening global market positions through strategic partnerships, regulatory approvals, and pipeline innovations focused on chronic and infectious diseases.

---

Request a free sample copy or view report summary: 
Inhalable Biologics Market Report

---

Inhalable Biologics Market Report Highlights

• Based on type, the peptides and proteins segment led the market with the largest revenue share of 29.85% in 2024, due to their broad therapeutic applications, stability improvements, and efficient pulmonary absorption.

• The RNAi-based therapeutics segment is projected to grow at a robust CAGR over the forecast period.

• Based on applications, the diabetes segment accounted with the largest market revenue share in 2024. However, respiratory diseases are expected to grow at a rapid CAGR over the forecast period.

• Based on dosage form, the dry powder inhalers segment accounted for the largest market revenue share in 2024, aided by approved products in the segment. However, the nebulizers segment is expected to witness at the fastest CAGR over the forecast period.

• Based on the distribution channel, the hospital pharmacies segment accounted for the largest market revenue share in 2024.

• In December 2024, Cipla received CDSCO approval on December 11, 2024, to exclusively distribute and market Afrezza (inhaled insulin) in India, developed by MannKind Corporation. Afrezza is a rapid-acting insulin for type 1 and type 2 diabetes, offering a non-injectable alternative with quick absorption and a 2-3 hour effect. Cipla aims to enhance diabetes management accessibility, leveraging its distribution network to improve patient outcomes across India.

Inhalable Biologics Market Segmentation

Grand View Research has segmented the global inhalable biologics market report based on the biologic, applications, dosage form, distribution channel, and region:

Inhalable Biologics Type Outlook (Revenue, USD Million, 2018 - 2030)

• Peptides and Proteins

• Vaccines

• Monoclonal Antibodies

• RNAi-based Therapeutics

• Others

Inhalable Biologics Application Outlook (Revenue, USD Million, 2018 - 2030)

• Respiratory diseases

  • COPD

  • Asthma

  • Cystic Fibrosis

  • COVID-19

  • Others

• Diabetes

• Cancer

• Others

Inhalable Biologics Dosage Form Outlook (Revenue, USD Million, 2018 - 2030)

• Dry Powder Inhalers

• Metered Dose Inhalers

• Nebulizers

• Others

Inhalable Biologics Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Teledermatology Market Size To Reach $41.08 Billion By 2030

 August 2025 | Report Format: Electronic (PDF)

Teledermatology Market Growth & Trends

The global teledermatology market size is anticipated to reach USD 41.08 billion by 2030 and is projected to grow at a CAGR of 17.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to grow due to the increasing smartphone adoption, rising prevalence of skin illnesses and skin-related issues, increased acceptance of telemedicine platforms, and growing internet penetration globally. As per WHO study published in March 2023, Skin conditions are a significant global health issue, affecting approximately 1.8 billion people at any given time. This statistic highlights the prevalence of various skin disorders, which can range from mild irritations to severe infections and chronic diseases.

Teledermatology offers a convenient, accessible way for patients to receive dermatological consultations remotely, leveraging technology to bridge the gap between patients and specialists. It allows patients to submit images of their skin conditions through secure platforms, where dermatologists can review and provide a diagnosis or treatment plan. This model improves access to care, particularly for those in rural or underserved areas, reduces wait times, and can help in early detection of skin diseases, including skin cancer. In addition, teledermatology can offer a cost-effective alternative to in-person visits while maintaining the quality and accuracy of medical care.

Moreover, the increasing usage of tele-dermatology platforms is the rising number of smartphone users and expanding internet access globally. According to the International Telecommunication Union, around 5 billion people have access to the internet, and most of them use smartphones to do it. In addition, the main market players’ efforts in digital marketing and social media marketing to expand their consumer bases have increased as a result of the social media’s increasing penetration. The availability of dermatologists and consultants on teledermatology platforms has increased due to the growing consumer use of telehealth.

---

Request a free sample copy or view report summary: Teledermatology Market Report

---

Teledermatology Market Report Highlights

• Based on modalities, the store and forward segment held the largest market share in 2024. This is attributed to store-and-forward technique which has become crucial for accurately recording skin photos.
• Based on service, the teleconsultation segment held the largest market share in 2024. This can be attributed to the two advancements in artificial intelligence (AI) and machine learning.
• Based on end use, the patients segment held the largest market share in 2024. This can be attributed to the fact that patients use telemedicine services for a variety of reasons, from minor to major situations.
• For instance, in December 2024, Omda AS, announced its acquisition of Dermicus AB, a company that specializes in telemedicine solutions focused on teledermatology and telewound care.

Teledermatology Market Segmentation

Grand View Research has segmented the global teledermatology market based on modalities, services, end use, and region:

Teledermatology Modalities Outlook (Revenue, USD Million, 2018 – 2030)

• Live Video
• Store-and-Forward
• Hybrid

Teledermatology Services Outlook (Revenue, USD Million, 2018 – 2030)

• Teleconsultation
• Telemonitoring
• Tele-education
• Others

Teledermatology End-Use Outlook (Revenue, USD Million, 2018 – 2030)

• Patients
• Providers